healthcare
FountainVest leads $32m round for China healthcare app
FountainVest Partners has led a RMB200 million ($32 million) round of funding for Xingren.com, a Chinese mobile app for doctors to communicate with patients. Existing investors Sequoia Capital and Lightspeed China Partners also participated.
Indian doctor search app Lybrate secures $10m
Tiger Global has led a $10.2 million Series B round investment in Indian doctor search app Lybrate.
Japan's Genesis Healthcare raises $5.1m from Founders Fund, Mitsui
US early stage investor Founders Fund and Japanese conglomerate Mitsui & Co have together invested JPY620 million ($5.1 million) in Genesis Healthcare, a Tokyo-based start-up that develops genetic testing kits, in exchange for a 6% stake.
Cathay Capital invests in European pharma firm Cenexi
Cathay Capital Private Equity has invested an undisclosed sum in Cenexi Group, a French pharmaceutical contract manufacturer.
Hosen targets $400m for China food and agri fund
China-focused food and agriculture specialist Hosen Capital is looking to raise $400 million for its second US dollar-denominated fund.
China healthcare: The specialists
On the back of reforms and a rising consumer class, China's healthcare sector is expected to see huge growth. Sector specialists have emerged to capitalize on the opportunity. How can they differentiate themselves?
Australia's PE-owned GenesisCare to buy Cancer Partners UK
Australian cancer and cardiovascular treatment provider GenesisCare, which is owned by KKR, has bought cancer center manager Cancer Partners UK from its private equity backer, Apposite Capital.
Qiming promotes William Hu to managing partner
China VC firm Qiming Venture Partners has promoted healthcare specialist William Hu to managing partner with immediate effect.
Novartis buys VC-backed Australian drug developer Spinifex
Australian life sciences specialists Brandon Capital Partners and GBS Ventures will exit local drug developer Spinifex Pharmaceuticals after Novartis agreed to buy the business for $200 million in cash plus unspecified earn-outs.
Former Matrix China director launches RMB VC fund
Roger Hu, a director at Matrix Partners China, has teamed up with Yi Zheng, formerly vice president at Chinese dating app Momo, to launch a renminbi-denominated early-stage fund.
Australia's Crescent to buy Healthscope pathology business
Crescent Capital Partners has agreed to acquire the Australian pathology operations of Healthscope for A$105 million ($80.8 million).
Singapore's Temasek, CVC agree $2b deal for US generic drug firm
Singapore's Temasek Holdings is a member of a CVC Capital Partners-led consortium that has agreed to buy a controlling stake in US-based generic drug manufacturer Alvogen. The deal is said to value the company at $2 billion.
PE-backed Wenzhou Kangning Hospital files for HK IPO
Wenzhou Kangning Hospital, the largest private psychiatric specialty care service provider in China backed by PE investors, has filed for an IPO in Hong Kong.
India's MyDentist raises $8m Series C round
Indian dental clinic chain MyDentist has raised a INR500 million ($8 million) funding round led by Swiss impact investor LGT Venture Philanthropy, with participation by existing backers Seedfund and Asian Healthcare Fund (AHF).
VC in Japan's universities: Getting schooled
For the past decade, Japan’s universities have been working with venture capital to commercialize their research. Recent developments in the public and private sectors suggest this relationship is evolving
Indian healthcare player La Renon raises $16m from Sequoia
La Renon, an Indian developer and manufacturer of pharmaceutical drugs and services, has raised INR1 billion ($16 million) in Series A funding from Sequoia Capital.
Sequoia's Shen joins China take-private wave
Neil Shen, managing partner at Sequoia Capital China, is supporting take-private bids for budget hotel operator Home Inns and online real estate agency E-House as a growing number of US-listed Chinese companies turn their attention to domestic listings.
Warburg Pincus in partial exit from China Biologic
Warburg Pincus has raised $241.5 million by reducing its stake in US-listed biopharmaceutical developer China Biologic Products.
KKR-owned Panasonic Healthcare agrees $1.1b Bayer bolt-on
Panasonic Healthcare, the Japanese medical equipment manufacturer in which KKR acquired a majority stake last year, has agreed to buy Bayer’s diabetes care business for EUR1.02 billion ($1.15 billion).
Morningside leads $15m investment in China's Luqa Pharma
Hong Kong-based pharmaceutical developer Luqa Pharma has raised a $15 million Series A round of funding led by Morningside Ventures.
Quadria closes maiden healthcare fund at $304m
Quadria Capital, the Singapore and India-based private equity firm, has reached a final close on its maiden healthcare fund at $304 million.
CITIC PE-backed 3SBio IPO raises $711m in Hong Kong IPO
CITIC Private Equity has made a partial exit from Chinese biotech player 3SBio as the company raised HK$5.51 billion ($711 million), two years after leaving NASDAQ in a take-private deal.
Fidelity leads round for India healthcare start-up Medwell
Fidelity Growth Partners India (FGPI) and affiliated US fund Fidelity Biosciences have invested $10 million in Medwell Ventures, operator of Nightingales specialty home healthcare services.
Chinese consortium to buy US biotech firm Ambrx
A consortium of Chinese investors including Shanghai Fosun Pharmaceutical Group, Hopu Investments, CEL Healthcare Fund and WuXi PharmaTech will acquire Ambrx, a US-based biotech pharmaceutical developer.